Qingdao Haiji Biopharmaceutical

Qingdao Haiji Biopharmaceutical is a Chinese biotechnology company established in 2019 as a joint venture between Qingdao Huanghai Pharmaceutical, the team of Academician Guan Huashi from Ocean University of China, and the Marine Biomedical Research Institute of Qingdao. Dedicated to the Blue Drugstore development plan, the company focuses on the research, development, and clinical translation of marine-derived innovative drugs. Its pipeline includes LY102, a marine-derived small molecule for chronic hepatitis B in Phase 1 clinical trials; LY103, a marine polysaccharide-derived compound for sepsis-induced coagulopathy with IND approval; and LY104, a marine bryozoan-derived small molecule for chronic obstructive pulmonary disease with IND approval. Leveraging its advanced drug discovery platform, the company accelerates the translation of marine natural products into novel therapeutics for viral, inflammatory, and metabolic diseases.